Novo Nordisk Stock - Deutsche Bank holds rating after strong run

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 22:53 CET. Details in the imprint.

Novo Nordisk (DK0060534915) remains on Deutsche Bank’s Hold list with a confirmed price target of DKK 290, according to a trading-floor update on Nasdaq Copenhagen dated 06/19/2026. The decision comes after another active week for European large-cap pharma names.

What Deutsche Bank signals

On the Nasdaq Copenhagen market overview for Novo Nordisk B, Deutsche Bank is listed as keeping its recommendation at Hold with a price objective of DKK 290 on 06/19/2026. The note follows a period of strong performance in obesity and diabetes therapies.

According to analyst-consensus data, Novo Nordisk still trades close to the average 12-month target, which MarketScreener currently places at roughly DKK 313 for the B shares, with a broad range between DKK 200 and DKK 454. This frames Deutsche Bank’s stance as relatively cautious versus the wider sell-side.

How the week looked for peers

Over the past five trading days, Novo Nordisk shares on Nasdaq Copenhagen and its New York listing under ticker NVO moved broadly in line with other major European pharma stocks, after a strong first half driven by demand for obesity drugs. Sector sentiment remained supported by ongoing prescription data and pipeline expectations.

On the New York Stock Exchange, Novo Nordisk’s ADR closed at $43.20 on 06/18/2026, with a marginal 0.02% gain on the day, and a market capitalization around $390 billion according to MarketBeat. For the week, flows into large-cap healthcare ETFs also stayed solid, underpinning valuations across the peer group.

How the company makes money

Novo Nordisk generates most of its revenue from diabetes and obesity care, led by GLP-1-based treatments such as semaglutide, marketed globally under brands including Ozempic for type 2 diabetes and Wegovy for obesity. A smaller segment covers rare disease therapies like hemophilia products.

Where the stock trades today

The shares of Novo Nordisk (DK0060534915) trade on Nasdaq Copenhagen at DKK 287.40 as of 06/19/2026, 16:00 CEST.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.